eConsent for Sponsors: What to Look for in CNS Trials
Direct answer
Sponsors evaluating eConsent for CNS trials should prioritize platforms that combine 21 CFR Part 11 compliant audit trails with built-in support for legally authorized representative signing, caregiver involvement, and comprehension checks. CNS studies often involve participants with cognitive impairment, longer protocols, and frequent re-consent, so the platform needs to scale that workflow across every site and country without losing version control.
What do sponsors need from an eConsent platform?
A sponsor is the entity legally responsible for a clinical trial, which means the eConsent platform it selects has to hold up under FDA inspection, not just work smoothly for participants. A few requirements come up in nearly every sponsor evaluation.
Does the platform support multi-site and multi-country deployment?
Most CNS trials enroll across dozens of sites and several countries, so the eConsent platform needs consistent workflows regardless of location. That means localized language support, region-specific consent language, and a single system of record so a monitor can see consent status at any site without chasing paper.
Is the audit trail complete and 21 CFR Part 11 compliant?
Under FDA guidance, sponsors remain responsible for the quality and integrity of data collected in a third-party system, even when that system is run by a vendor. The audit trail needs to record who signed, when, which version of the consent form they saw, and what changed between versions. Version mismatches between what a participant signed and what is on file are a common inspection finding, so gaps here carry real regulatory risk.
How does the platform coordinate with IRBs across sites?
Multi-site studies typically involve several institutional review boards, each of which needs to review and approve consent language and any amendments. A platform that supports centralized version management, so every site is presented with the current IRB-approved form, reduces the chance that a site collects a signature on outdated language.
Can the platform manage version control and re-consent at scale?
Protocol amendments happen often in long-running trials, and each one can trigger a re-consent event across every enrolled participant. Sponsors need a way to track who has re-consented, who has not, and which version each participant last signed, without relying on site staff to manually track spreadsheets.
What makes CNS trials different for eConsent?
Central nervous system trials, covering conditions like Alzheimer's disease, Parkinson's disease, and other neurodegenerative or psychiatric disorders, raise informed consent challenges that are less common in other therapeutic areas.
Why do CNS trials often need legally authorized representative consent?
Many CNS conditions affect memory, reasoning, or judgment, which can compromise a participant's capacity to provide informed consent. Federal regulations allow a legally authorized representative to consent on the participant's behalf when the participant is determined to lack decisional capacity, using substituted judgment based on what is known of that person's wishes. An eConsent platform used for CNS trials needs a workflow that supports LAR identity verification, LAR signature capture, and, where appropriate, documented assent from the participant as well.
How does caregiver involvement affect the consent process?
CNS study protocols frequently require a caregiver or study partner to attend visits, support comprehension of study information, and help monitor safety over time. Some protocols formally define the caregiver's role and may require the caregiver to sign their own consent to participate in caregiver-specific assessments. An eConsent platform built for CNS work should be able to route separate consent documents to the participant and the caregiver while keeping both records linked in the audit trail.
Why is comprehension support more important in CNS trials?
Even participants who retain decisional capacity may need extra support to fully understand a lengthy or complex protocol, particularly in early-stage cognitive decline where capacity can fluctuate. Interactive consent elements such as plain-language summaries, video explanations, and comprehension quizzes give investigators a documented way to confirm understanding before a signature is captured, which supports both participant protection and inspection readiness.
Why do CNS protocols involve more frequent re-consent?
CNS trials often run longer than trials in other therapeutic areas and may include multiple protocol amendments as dosing, safety monitoring, or endpoints evolve. Combined with a population where capacity can change over the course of the study, this means re-consent events happen more often and need extra care, sometimes requiring a fresh capacity assessment before the LAR or participant re-signs.
How do the leading eConsent platforms compare for sponsors?
The table below compares Curebase with five other established eConsent providers on the factors that matter most to sponsors: multi-site and multi-country reach, Part 11 audit trail depth, and re-consent handling. All platforms listed are currently operating in the clinical trials market.
| Platform | Best fit | Multi-site and multi-country | Part 11 audit trail | Re-consent workflow |
|---|---|---|---|---|
| Curebase | Sponsors running decentralized or hybrid CNS trials that need consent tied to comprehension support and downstream data flows | Yes, global multi-site studies across regulatory jurisdictions | Yes, end-to-end audit trail with version control and role-based access | Automated workflow with tracked acknowledgment, built for high re-consent protocols |
| Medidata (Rave and Medidata Consent) | Large enterprise sponsors already standardized on the Medidata ecosystem | Yes, built for large multi-region registrational trials | Yes, strong Part 11 and audit trail support | Yes, supports re-consent and pediatric assent workflows |
| Veeva (SiteVault eConsent) | Sponsors and sites already using Veeva Vault for eTMF and site management | Yes, available to investigator sites within the Veeva ecosystem | Yes, Part 11 and HIPAA compliant | Supported through in-person and remote signing workflows |
| Signant Health (SmartSignals eConsent) | Multi-country trials that also need eCOA and patient engagement tools in one suite | Yes, positioned for multi-country deployments | Yes | Yes, integrated with broader eCOA re-consenting triggers |
| Florence Healthcare (Florence eConsent) | Sponsors and sites that already rely on Florence eBinders for regulatory documents | Supports global study management with remote monitor access | Yes, audit trails, version control, and signature verification | Yes, distributes and tracks re-consent from a single platform |
| Medrio | Smaller sponsors that want eConsent alongside Electronic Data Capture and ePRO | Yes, supports remote and site-based consent across regions | Yes, Part 11 compliant electronic signatures and audit history | Supported, with version tracking tied to study configuration changes |
Where does Curebase fit for sponsors running CNS trials?
Curebase eConsent is built to connect signed consent directly into the rest of a study, so a participant who signs flows straight into screening, scheduling, and ongoing data collection without a manual hand-off. For sponsors running CNS trials, that matters because consent is rarely a one-time event: the platform's automated re-consent workflow with tracked acknowledgment is designed for protocols that amend often, and its drag-and-drop builder lets a study team update consent language quickly when an IRB approves a change.
Interactive elements, including video, images, and comprehension quizzes, give investigators a documented way to support participant understanding before signing, which is particularly relevant when a study population may include participants with fluctuating cognitive capacity. Curebase eConsent supports global multi-site studies across regulatory jurisdictions with 40 to 50 languages built in, and it maintains a complete, end-to-end 21 CFR Part 11 audit trail with version control and role-based access, so sponsors can show exactly which consent version each participant, or their legally authorized representative, signed.
See the Curebase eConsent product page for a full feature breakdown, or read the related guide on eConsent requirements for clinical trials.
Frequently asked questions
What is eConsent in clinical trials?
eConsent, or electronic informed consent, replaces paper consent forms with a digital process that presents study information, checks comprehension, and captures a legally valid electronic signature. It covers the full consent lifecycle, including initial signing, version tracking, and re-consent when a protocol changes.
What should sponsors look for in an eConsent platform?
Sponsors should prioritize a validated 21 CFR Part 11 audit trail, support for multi-site and multi-country deployment, centralized version control that stays aligned with IRB-approved consent language, and a straightforward way to manage re-consent when protocols are amended. Integration with Electronic Data Capture and other clinical systems reduces manual data entry and keeps consent status visible across the study.
How does eConsent support legally authorized representative (LAR) consent?
A well-built eConsent platform lets a legally authorized representative complete identity verification and sign on behalf of a participant who lacks decisional capacity, while keeping that signature event and the reasoning behind it in the audit trail. Many platforms also support capturing participant assent alongside the LAR signature when appropriate.
Why are CNS trials different from other therapeutic areas when it comes to consent?
CNS trials often enroll participants with conditions that can affect memory, reasoning, or judgment, so capacity to consent may be diminished or may change during the study. These trials also tend to involve caregivers, LAR consent workflows, and more frequent re-consent tied to protocol amendments, all of which place extra demands on an eConsent platform compared to trials in less cognitively affected populations.
Is Curebase eConsent 21 CFR Part 11 compliant?
Yes. Curebase eConsent is designed to FDA 21 CFR Part 11 and ICH GCP standards, with validated electronic signatures, identity verification, and a complete audit trail of every view, edit, and signature event. It is also GDPR compliant and SOC 2 Type II certified.
Can eConsent handle re-consent for long-running or frequently amended studies?
Yes. Modern eConsent platforms, including Curebase, offer automated re-consent workflows that notify participants of an amended form, track who has acknowledged the update, and preserve a version history showing exactly which document each participant signed and when. This is especially important in CNS trials, where amendments and extended timelines make re-consent a recurring event rather than a one-time step.
